Aviceda To Present at Major European Healthcare Conferences Highlighting AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration
Aviceda Therapeutics, a privately held, late-stage clinical biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to alleviate chronic non-resolving inflammation, announced today multiple upcoming presentations about its lead ophthalmic clinical asset, AVD-104. The groundbreaking glycan-coated nanoparticle designed to combat geographic atrophy (GA) resulting from age-related macular degeneration (AMD) will take the spotlight at various European conferences, featuring comprehensive corporate and clinical updates from company executives and principal investigators between Wednesday, October 4 and Saturday, October 7, 2023.
Though the SIGLEC trial recently began in June of this year, Aviceda has already completed the dose-escalation enrollment for all cohorts in Part 1. Part 2 of the Phase 2/3 SIGLEC clinical trial looks to begin enrollment in November 2023.
To learn more about the SIGLEC trial, click here.
About Aviceda Therapeutics and AVD-104
Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including neurology, oncology, fibrosis and immunology.